Actinogen Medical Ltd (ACW) - Net Assets
Based on the latest financial reports, Actinogen Medical Ltd (ACW) has net assets worth AU$18.34 Million AUD (≈ $12.97 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$24.48 Million ≈ $17.32 Million USD) and total liabilities (AU$6.15 Million ≈ $4.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ACW asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$18.34 Million |
| % of Total Assets | 74.9% |
| Annual Growth Rate | 41.82% |
| 5-Year Change | 5.03% |
| 10-Year Change | 51.22% |
| Growth Volatility | 409.3 |
Actinogen Medical Ltd - Net Assets Trend (2006–2025)
This chart illustrates how Actinogen Medical Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Actinogen Medical Ltd for the complete picture of this company's asset base.
Annual Net Assets for Actinogen Medical Ltd (2006–2025)
The table below shows the annual net assets of Actinogen Medical Ltd from 2006 to 2025. For live valuation and market cap data, see Actinogen Medical Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$18.34 Million ≈ $12.97 Million |
-6.91% |
| 2024-06-30 | AU$19.70 Million ≈ $13.94 Million |
+46.91% |
| 2023-06-30 | AU$13.41 Million ≈ $9.49 Million |
-38.33% |
| 2022-06-30 | AU$21.74 Million ≈ $15.38 Million |
+24.53% |
| 2021-06-30 | AU$17.46 Million ≈ $12.35 Million |
+60.33% |
| 2020-06-30 | AU$10.89 Million ≈ $7.70 Million |
-30.49% |
| 2019-06-30 | AU$15.66 Million ≈ $11.08 Million |
-9.23% |
| 2018-06-30 | AU$17.26 Million ≈ $12.21 Million |
+84.27% |
| 2017-06-30 | AU$9.37 Million ≈ $6.63 Million |
-22.76% |
| 2016-06-30 | AU$12.13 Million ≈ $8.58 Million |
-21.04% |
| 2015-06-30 | AU$15.36 Million ≈ $10.87 Million |
+1167.24% |
| 2014-06-30 | AU$1.21 Million ≈ $857.43K |
+523.51% |
| 2013-06-30 | AU$194.35K ≈ $137.52K |
-43.99% |
| 2012-06-30 | AU$346.99K ≈ $245.52K |
-66.83% |
| 2011-06-30 | AU$1.05 Million ≈ $740.20K |
-10.45% |
| 2010-06-30 | AU$1.17 Million ≈ $826.62K |
-38.58% |
| 2009-06-30 | AU$1.90 Million ≈ $1.35 Million |
-33.47% |
| 2008-06-30 | AU$2.86 Million ≈ $2.02 Million |
+1274.60% |
| 2007-06-30 | AU$208.00K ≈ $147.17K |
+766.67% |
| 2006-06-30 | AU$24.00K ≈ $16.98K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Actinogen Medical Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9646809800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$101.25 Million | 552.19% |
| Other Comprehensive Income | AU$13.56 Million | 73.93% |
| Total Equity | AU$18.34 Million | 100.00% |
Actinogen Medical Ltd Competitors by Market Cap
The table below lists competitors of Actinogen Medical Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kortek Corporation
KQ:052330
|
$105.76 Million |
|
Faraday Future Intelligent Electric Inc
NASDAQ:FFIE
|
$105.77 Million |
|
Tian Zheng International Precision Machinery Co Ltd
TWO:6654
|
$105.78 Million |
|
Soluna Holdings Inc
NASDAQ:SLNH
|
$105.81 Million |
|
RoboRobo Co. Ltd
KQ:215100
|
$105.70 Million |
|
EDAP TMS S.A
F:EDA
|
$105.70 Million |
|
RS Automation Co.Ltd
KQ:140670
|
$105.68 Million |
|
WooriNet Inc
KQ:115440
|
$105.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Actinogen Medical Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,696,499 to 18,335,903, a change of -1,360,596 (-6.9%).
- Net loss of 14,732,263 reduced equity.
- Share repurchases of 529,846 reduced equity.
- New share issuances of 12,237,808 increased equity.
- Other comprehensive income increased equity by 12,147,072.
- Other factors decreased equity by 10,483,367.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-14.73 Million | -80.35% |
| Share Repurchases | AU$529.85K | -2.89% |
| Share Issuances | AU$12.24 Million | +66.74% |
| Other Comprehensive Income | AU$12.15 Million | +66.25% |
| Other Changes | AU$-10.48 Million | -57.17% |
| Total Change | AU$- | -6.91% |
Book Value vs Market Value Analysis
This analysis compares Actinogen Medical Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.64x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.37x to 7.64x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-06-30 | AU$0.13 | AU$0.05 | x |
| 2009-06-30 | AU$0.08 | AU$0.05 | x |
| 2010-06-30 | AU$0.05 | AU$0.05 | x |
| 2011-06-30 | AU$0.05 | AU$0.05 | x |
| 2012-06-30 | AU$0.01 | AU$0.05 | x |
| 2013-06-30 | AU$0.00 | AU$0.05 | x |
| 2014-06-30 | AU$0.01 | AU$0.05 | x |
| 2015-06-30 | AU$0.04 | AU$0.05 | x |
| 2016-06-30 | AU$0.02 | AU$0.05 | x |
| 2017-06-30 | AU$0.01 | AU$0.05 | x |
| 2018-06-30 | AU$0.02 | AU$0.05 | x |
| 2019-06-30 | AU$0.01 | AU$0.05 | x |
| 2020-06-30 | AU$0.01 | AU$0.05 | x |
| 2021-06-30 | AU$0.01 | AU$0.05 | x |
| 2022-06-30 | AU$0.01 | AU$0.05 | x |
| 2023-06-30 | AU$0.01 | AU$0.05 | x |
| 2024-06-30 | AU$0.01 | AU$0.05 | x |
| 2025-06-30 | AU$0.01 | AU$0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Actinogen Medical Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -268.37%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.34x
- Recent ROE (-80.35%) is below the historical average (-72.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -15.24% | -279.49% | 0.05x | 1.03x | AU$-721.58K |
| 2009 | -48.73% | -723.46% | 0.06x | 1.06x | AU$-1.12 Million |
| 2010 | -63.13% | -794.68% | 0.07x | 1.15x | AU$-854.30K |
| 2011 | -70.96% | -785.98% | 0.08x | 1.09x | AU$-846.99K |
| 2012 | -440.69% | -2965.66% | 0.11x | 1.34x | AU$-1.56 Million |
| 2013 | -84.72% | -5308.28% | 0.01x | 1.42x | AU$-184.10K |
| 2014 | -36.33% | -242.94% | 0.14x | 1.04x | AU$-561.40K |
| 2015 | -35.37% | -3539.75% | 0.01x | 1.01x | AU$-6.97 Million |
| 2016 | -29.97% | -91.93% | 0.31x | 1.07x | AU$-4.85 Million |
| 2017 | -34.06% | -225.39% | 0.14x | 1.09x | AU$-4.13 Million |
| 2018 | -36.10% | -188.76% | 0.18x | 1.04x | AU$-7.96 Million |
| 2019 | -63.12% | -203.33% | 0.30x | 1.04x | AU$-11.45 Million |
| 2020 | -48.96% | -151.59% | 0.29x | 1.10x | AU$-6.42 Million |
| 2021 | -22.43% | -197.32% | 0.11x | 1.05x | AU$-5.66 Million |
| 2022 | -43.69% | -260.91% | 0.16x | 1.07x | AU$-11.67 Million |
| 2023 | -80.20% | -219.98% | 0.32x | 1.13x | AU$-12.09 Million |
| 2024 | -66.23% | -131.34% | 0.47x | 1.08x | AU$-15.01 Million |
| 2025 | -80.35% | -268.37% | 0.22x | 1.34x | AU$-16.57 Million |
Industry Comparison
This section compares Actinogen Medical Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,485,259
- Average return on equity (ROE) among peers: -74.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Actinogen Medical Ltd (ACW) | AU$18.34 Million | -15.24% | 0.34x | $105.70 Million |
| Adalta Ltd (1AD) | $3.70 Million | -162.25% | 0.87x | $6.50 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $-1.33 Million | 0.00% | 0.00x | $20.04 Million |
| ACRUX Ltd (ACR) | $12.85 Million | -73.71% | 0.44x | $3.20 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $15.45 Million |
| Arovella Therapeutics Ltd (ALA) | $11.03 Million | -40.87% | 0.23x | $58.08 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $20.73 Million | -6.40% | 0.01x | $76.95 Million |
| Amplia Therapeutics Ltd (ATX) | $11.23 Million | -30.16% | 0.02x | $50.82 Million |
| Avecho Biotechnology Ltd (AVE) | $3.27 Million | -95.48% | 0.53x | $28.59 Million |
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more